Ascendis

– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism COPENHAGEN, Denmark, June 05, 2023 (GLOBE NEWSWIRE)…

–   On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its…

-   The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States -   TransCon PTH is under…

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference. Details: Event41st Annual J.P.…

- SKYTROFA® U.S. revenue more than doubled quarter-to-quarter again, reaching €12.3 million in the third quarter - FDA accepted for Priority Review TransCon™ PTH NDA in adult patients with hypoparathyroidism; target action PDUFA date is…

New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH - Initial findings from research on comorbidities associated with…

–  For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). –  TransCon PTH demonstrated statistically significant improvements compared to control on all…

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S…

– TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency. – Final European Commission decision on TransCon hGH MAA for pediatric growth hormone deficiency…

– Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company’s Phase 2 PaTH Forward Trial – COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a…